We appreciate the correspondence from Wang and Zhong[1] and Agargün and Cavus[2] regarding our report on the first pig-to-human auxiliary liver xenotransplantation[3]. Here we address their questions with additional single-nucleus RNA sequencing (snRNA-seq) data from the explanted xenograft and portal hemodynamic assessments, focusing on the distinction between xenotransplantation-associated thrombotic microangiopathy (xTMA) and antibody-mediated rejection (AMR).
Journal of Hepatology published a clinical update in Research Highlights on 17 Mar 2026.
The item focuses on Reply to: “Thrombotic microangiopathy or rejection in first pig-to-human patient liver xenotransplantation” and “Progress and Remaining Barriers in Liver Xenotransplantation”.
Review the original article for the full source wording and details.